CEL-SCI Corporation, a clinical stage cancer immunotherapy company, has announced the closing of a $5.7 million offering under NYSE American rules. The company sold 1,500,000 shares of its common stock at $3.82 per share. The proceeds from the offering are intended to support the continued development of CEL-SCI's Multikine product, as well as for general corporate purposes and working capital. ThinkEquity acted as the sole placement agent for this offering. The securities were offered under a shelf registration statement filed with the U.S. Securities and Exchange Commission.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.